Shanghai Thermo Biotechnology

Shanghai SIMR Biotechnology Co., Ltd. (SIMR) is a biopharmaceutical company established in 2014, focusing on the development of novel drugs for pain, inflammation, and diseases of the central nervous system. The company was founded by Dr. Li Shuai, who now serves as CEO. Dr. Li's decision to establish SIMR stemmed from a desire to translate his 12 years of basic research in chronic pain at the Chinese Academy of Sciences (CAS) into clinical products that could directly benefit patients.

SIMR operates on a business model centered around in-house research and development, progressing drug candidates from discovery to clinical trials. Its R&D platform, spanning over 3,000 square meters, supports a wide range of activities including compound screening, preclinical evaluation, and clinical development. The company's revenue generation is anticipated through the successful commercialization of its drug pipeline and strategic partnerships for co-development and out-licensing of its assets. SIMR is a privately held, venture capital-backed entity that has successfully raised significant capital, including a Series C1 financing of 150 million Chinese Yuan in November 2022 to advance its clinical trials.

The company's core business involves creating a diversified pipeline of therapies. A key product in development is SR419, a drug candidate with a novel mechanism of action for treating peripheral neuropathic pain. This condition represents a significant unmet medical need, as current treatments are not effective for a large percentage of patients. SIMR has advanced SR419 through first-in-human studies and received approval from the U.S. FDA for a Phase II clinical study in December 2021. The company's strategy involves a translational approach, utilizing patient data and animal models to inform target discovery and clinical design, with a global development strategy that includes pursuing clinical trials in Australia, China, and the United States.

Keywords: biopharmaceutical, drug development, central nervous system, pain management, inflammation, neuropathic pain, clinical trials, drug discovery, translational medicine, SR419, neurodegenerative diseases, Li Shuai, venture capital, pharmaceutical compounds, CNS disorders, preclinical evaluation, clinical development, therapeutics, first-in-class assets, biopharma